Compare ALGT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGT | MESO |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2006 | 2005 |
| Metric | ALGT | MESO |
|---|---|---|
| Price | $74.64 | $14.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $117.43 | $37.00 |
| AVG Volume (30 Days) | ★ 410.4K | 269.1K |
| Earning Date | 11-04-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.62 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,606,579,000.00 | N/A |
| Revenue This Year | $42.77 | $51.63 |
| Revenue Next Year | $22.28 | $63.39 |
| P/E Ratio | $41.40 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $61.36 | $11.89 |
| 52 Week High | $123.63 | $21.50 |
| Indicator | ALGT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 57.35 |
| Support Level | $72.89 | $13.77 |
| Resistance Level | $85.94 | $16.06 |
| Average True Range (ATR) | 3.84 | 0.47 |
| MACD | 1.04 | 0.34 |
| Stochastic Oscillator | 80.25 | 82.19 |
Allegiant Travel Co is a leisure travel company focused on providing travel and leisure services and products to residents of underserved cities in the United States. It operates a low-cost, low utilization passenger airline marketed to leisure travelers in underserved cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third-party services and products. In addition, it provides air transportation under fixed-fee flight arrangements. In connection with its leisure travel focus, the company has opened Sunseeker Resort Charlotte Harbor, equipped with several guestrooms and food and beverage outlets. The company's operating segments are the Airline, which generates the maximum revenue, and Sunseeker Resort.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.